Antibody treatment of Alzheimer's and related diseases
Provided is an antibody that selectively binds to an epitope formed by residues 1-11 of Aβ in an Aβ oligomer, a method comprising using the antibody to treat a disease characterized by such an Aβ amyloid deposit in a patient, and kits comprising same.
1. An isolated murine antibody that selectively binds to an epitope comprising residues 1-11 of human Aβ in an Aβ oligomer and does not recognize neurofibrillary tangles or Lewy bodies, wherein the antibody is monoclonal antibody NAB61.
2. The antibody of claim 1 , wherein the Aβ oligomer is a dimer, trimer or tetramer.
3. The antibody of claim 1 , wherein the Aβ oligomer is found in, or selected from, a mature senile plaque or a pathologic Aβ deposit.
4. A pharmaceutical composition, comprising an isolated murine antibody that selectively binds to an epitope comprising residues 1-11 of human Aβ in an Aβ oligomer and does not recognize neurofibrillary tangles or Lewy bodies, wherein the antibody is monoclonal antibody NAB61, and a pharmaceutical carrier.
5. The pharmaceutical composition of claim 4 , wherein the Aβ oligomer is a dimer, trimer or tetramer.
6. The pharmaceutical composition of claim 4 , wherein the Aβ oligomer is found in, or selected from, a mature senile plaque or a pathologic Aβ deposit.
7. A kit for selectively detecting an Aβ oligomer, the kit comprising an isolated murine antibody that selectively binds to an epitope formed by residues 1-11 of human Aβ in the Aβ oligomer and does not recognize neurofibrillary tangles or Lewy bodies, wherein the antibody is monoclonal antibody NAB61, and instructional material.
8. The kit of claim 7 , wherein the Aβ oligomer is a dimer, trimer or tetramer.
9. An isolated antibody that selectively binds to an epitope comprising residues 1-11 of human Aβ in an Aβ oligomer and does not recognize neurofibrillary tangles or Lewy bodies, wherein the antibody is a humanized version of monoclonal antibody NAB61.
10. A pharmaceutical composition comprising the humanized antibody of claim 9 .
11. A kit for selectively detecting an Aβ oligomer, the kit comprising the humanized antibody of claim 9 , and instructional material.
12. A hybridoma cell line from which monoclonal antibody NAB61 is produced.
13. A method for treating a disease characterized by an amyloid deposit of Aβ in a patient, the method comprising administering to such patient in need thereof a therapeutically effective amount of an antibody that selectively binds to an epitope comprising residues 1-11 of Aβ in an Aβ oligomer and does not recognize neurofibrillary tangles or Lewy bodies, wherein the antibody is monoclonal antibody NAB61.
14. The method of claim 13 , wherein the Aβ oligomer is a dimer, trimer or tetramer.
15. The method of claim 13 , wherein the Aβ oligomer is found in, or selected from, a mature senile plaque or a pathologic Aβ deposit.
16. The method of claim 13 , wherein the disease is Alzheimer's disease.
17. The method of claim 13 , wherein the patient is human.
18. A method for treating a disease characterized by an amyloid deposit of Aβ in a patient, the method comprising administering to such patient in need thereof a therapeutically effective amount of an antibody that selectively binds to an epitope comprising residues 1-11 of Aβ in an Aβ oligomer and does not recognize neurofibrillary tangles or Lewy bodies, wherein the antibody is a humanized version of monoclonal antibody NAB61.